Clinical Trials Browser

Breast Neoplasms, Urologic Neoplasms

NCT03420963 2026-03-20

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

NCT02675829 2026-03-04

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Phase 2 Active not recruiting

131 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

NCT05946993 2026-03-04

LIAM Mc

Phase NA Active not recruiting

72 enrolled

Genitourinary

Kidney Neoplasms, Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Testicular Neoplasms, Urologic Neoplasms

NCT05192837 2026-02-27

PORTICO

Phase NA Terminated

251 enrolled

GenitourinaryHead & Neck

Smoking Reduction, Head and Neck Neoplasms, Neoplasms, Postoperative Complications, Smoking, Urologic Neoplasms, Smoking Cessation

NCT07416630 2026-02-24

Web-Based Application for Monitoring Radiation Therapy Complications in Cancer Patients

Phase NA Recruiting

30 enrolled

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT04731376 2026-02-11

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Phase 1 Active not recruiting

56 enrolled

Genitourinary

Hypogonadism, Urologic Diseases, Urologic Neoplasms

NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Phase 2 Active not recruiting

32 enrolled

Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

NCT06680089 2025-12-31

CD70-targeted immunoPET Imaging of Kidney Cancer

Phase 2 Recruiting

300 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms, Urogenital Neoplasms, Urologic Neoplasms

NCT07305142 2025-12-26

Comparison of the Integrated Posterior-Anterior-Lateral Approach and the Posterior Approach in Robotic Radical Prostatectomy

Phase NA Completed

60 enrolled

Genitourinary

Urologic Neoplasms

NCT02276924 2025-12-24

UROVISIO

Phase NA Completed

29 enrolled

Genitourinary

Multicystic renal dysplasia, bilateral, Hematuria, Urologic Neoplasms, Nephrolithiasis

NCT06353906 2025-12-08

PRIAM

Phase 2 Recruiting

27 enrolled

Genitourinary

Penile Neoplasms, Urogenital Neoplasms, Urologic Neoplasms, Male Urogenital Diseases

NCT07252882 2025-11-28

UUTICaD

Phase NA Not yet recruiting

178 enrolled

Genitourinary

Urologic Neoplasms

NCT06545188 2025-11-24

MOST-D

Phase NA Completed

746 enrolled

Genitourinary

Necrophobia, Urologic Neoplasms

NCT03093909 2025-11-10

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Phase 1 Recruiting

44 enrolled

DermatologicGenitourinarySarcoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT05241340 2025-10-24

RAD-VACCINE

Phase 2 Active not recruiting

33 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT07216456 2025-10-15

Vaginal Dilator Therapy After Pelvic Radiation

Phase NA Not yet recruiting

88 enrolled

GenitourinaryGynecologic

Pelvic Neoplasms, Urologic Neoplasms

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT06237920 2025-09-03

TURANDORELA

Phase 2 Recruiting

90 enrolled

Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT04442724 2025-08-14

FMBRT

Phase NA Recruiting

60 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT05920343 2025-07-10

PREVENT-GU

Phase 2/3 Recruiting

120 enrolled

Classical hematologyGenitourinary

Urogenital Neoplasms, Urologic Neoplasms, Venous Thromboembolism

NCT02836795 2025-06-08

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

DermatologicGenitourinary

Melanoma, Urologic Neoplasms

NCT03473730 2025-01-30

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Phase EARLY_PHASE1 Completed

17 enrolled

Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

NCT06427057 2024-05-23

A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Phase 2 Not yet recruiting

40 enrolled

Genitourinary

Urologic Neoplasms

NCT03305627 2024-05-08

PAPRAC

Phase NA Completed

196 enrolled

Genitourinary

Postoperative Complications, Surgical Wound Infection, Urologic Neoplasms

NCT06357416 2024-05-01

MV

Phase NA Recruiting

4,000 enrolled

Genitourinary

Alcoholism, Urinary Bladder Neoplasms, Diabetes Mellitus, Hypertension, Kidney Neoplasms, Prostatic Neoplasms, Smoking, Testicular Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT04088968 2024-03-22

STRONG-CS

Phase NA Unknown

100 enrolled

GenitourinaryOther

Alcohol Drinking, Motor Activity, Obesity, Postoperative Complications, Smoking, Urologic Neoplasms, Risk Reduction Behavior, Malnutrition, Patient Preference

NCT05726136 2024-03-18